



Vivaris Capital launches first structure to 'bring novel treatments to patients'

North America | Products

🕒 10 Jun 2020 by Lavanya Nair & Pablo Conde

Private equity firm Vivaris Capital announced its first structured financial product for United Cancer Centres (UCC) which provides investors with alternative asset investments while securing their principal.

The Vican combines a private equity investment with investment-grade securities, and gives clients the chance to invest in scenarios with high growth and return potential while only taking the risk of an investment grade fixed-income portfolio.

"We take the investment proceeds and put half of it into a portfolio of securities that returns the face amount of the principal investment at the end of a term which is typically seven to 10 years," said president and founder of Vivaris, Christopher Mizer (*pictured*).

The face amount will be returned regardless of the performance of the portfolio company. The investments include zero coupon notes, treasury bonds and some insurance products.

"The other half goes into risk assets which, at the early stage, are technology-based growth equity companies. They're middle-market buyouts or their real estate development projects and have a current yield component that's designed to pay investors about a six percent coupon after a ramp-up period," said Mizer.

Underwriting is designed to give investors a 15% annualised return on investment plus additional upside from interest, dividends, share redemption and capital appreciation.

UCC is the first institutional healthcare system in the US that offers integrative cancer care under recently enacted 'right to try' legislation. This gives patients the chance to opt for therapies that have cleared a phase I clinical trial for safety but have not received approval from the US Food and Drug Administration (FDA) agency.

"FDA approval typically takes about 10 years and costs about a billion dollars but there are many medicines that are in development that could become a standard of care in the next decade," said Mizer.

UCC was founded by the owners of Chipsa Hospital, an integrative care clinic based in Playas Tijuana, Mexico. Annually, around 15,000 inquiries are sent its way from cancer patients on the topic of alternatives to standard care.

Vivaris has created the product as a special purpose vehicle to bring novel treatments to patients who are in desperate need of them and allows investors to support the cause while providing potential for capital appreciation and principal security.

Tags

Structured products

Special purpose vehicle

private equity

Related Articles

Blockchain investment platform rolls out crypto tracker to support medical research>

🕒 19 Nov 2019

Financing streaming content using structured products>

🕒 30 Mar 2020

Bridging the gap: some clients see advantages in off-balance sheet assets>

🕒 30 Apr 2020